Loading the session
Loading the session
Loading instrument
$30.50
+0.00%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:39 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
Closed at $30.50 on 4 Nov 2026: 4.4% below the 52-week high of $31.91 (4 Nov 2026) and 75.9% above the low of $17.34 (13 Apr 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
4 Nov 2026 volume of 1.9M shares was 4.7× the average of the 30 sessions before it (399.5K), as the price rose 5.1%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
3.4M shares were sold short at the 15 Oct 2026 settlement; covering them would take 12.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
1 month: +12.5% (SPY −1.6%, XLV +13.5%). 3 months: +21.7% (SPY −0.4%, XLV +15.5%). 1 year: +14.4% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: KMTS, SPY and XLV · as of 4 Nov 2026
The 4 Nov 2026 close of $30.50 was 13.5% above its 50-day average ($26.86) and 27.5% above its 200-day average ($23.92). It has closed above the 200-day for 38 sessions, since 14 Sep 2026. The 50-day average crossed above the 200-day on 14 Aug 2026, 57 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Kestra Medical Technologies Ltd is a commercial-stage wearable medical device and digital healthcare company focused on connected monitoring, therapeutic intervention, and data-driven clinical insights for cardiovascular disease. It has developed and is commercializing the Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery. The platform is anchored by the ASSURE Wearable Cardioverter Defibrillator (WCD), which continuously monitors patient heart rhythms and automatically delivers defibrillation therapy when life-threatening ventricular arrhythmias are detected. The platform also includes digital patient engagement and clinical workflow solutions.
June 26, 2026
+17.05%September 12, 2025
+18.64%March 17, 2025
+16.50%